vs

Side-by-side financial comparison of CRYO CELL INTERNATIONAL INC (CCEL) and Forian Inc. (FORA). Click either name above to swap in a different company.

Forian Inc. is the larger business by last-quarter revenue ($8.0M vs $7.8M, roughly 1.0× CRYO CELL INTERNATIONAL INC). Forian Inc. runs the higher net margin — -22.9% vs -48.7%, a 25.8% gap on every dollar of revenue. On growth, Forian Inc. posted the faster year-over-year revenue change (37.0% vs -2.3%). Over the past eight quarters, Forian Inc.'s revenue compounded faster (27.8% CAGR vs -0.1%).

Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.

Forian Inc is a specialized healthcare technology and data analytics firm offering SaaS-based real-world evidence solutions, clinical decision support tools, and operational optimization services. It serves biopharmaceutical companies, healthcare providers, and life sciences stakeholders to improve patient outcomes, accelerate research, and boost care delivery efficiency.

CCEL vs FORA — Head-to-Head

Bigger by revenue
FORA
FORA
1.0× larger
FORA
$8.0M
$7.8M
CCEL
Growing faster (revenue YoY)
FORA
FORA
+39.2% gap
FORA
37.0%
-2.3%
CCEL
Higher net margin
FORA
FORA
25.8% more per $
FORA
-22.9%
-48.7%
CCEL
Faster 2-yr revenue CAGR
FORA
FORA
Annualised
FORA
27.8%
-0.1%
CCEL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCEL
CCEL
FORA
FORA
Revenue
$7.8M
$8.0M
Net Profit
$-3.8M
$-1.8M
Gross Margin
77.9%
49.2%
Operating Margin
-50.6%
-24.4%
Net Margin
-48.7%
-22.9%
Revenue YoY
-2.3%
37.0%
Net Profit YoY
-105.1%
-1012.2%
EPS (diluted)
$-0.46
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCEL
CCEL
FORA
FORA
Q4 25
$7.8M
$8.0M
Q3 25
$7.8M
$7.8M
Q2 25
$7.9M
$7.5M
Q1 25
$8.0M
$7.1M
Q4 24
$8.0M
$5.8M
Q3 24
$8.1M
$4.7M
Q2 24
$8.0M
$4.8M
Q1 24
$7.9M
$4.9M
Net Profit
CCEL
CCEL
FORA
FORA
Q4 25
$-3.8M
$-1.8M
Q3 25
$749.4K
$-151.2K
Q2 25
$355.8K
$224.8K
Q1 25
$282.9K
$-1.1M
Q4 24
$-1.9M
$199.7K
Q3 24
$1.1M
$-204.9K
Q2 24
$655.8K
$-2.6M
Q1 24
$556.2K
$-1.2M
Gross Margin
CCEL
CCEL
FORA
FORA
Q4 25
77.9%
49.2%
Q3 25
77.0%
51.6%
Q2 25
76.6%
56.8%
Q1 25
75.1%
55.6%
Q4 24
78.4%
58.3%
Q3 24
73.6%
70.1%
Q2 24
74.8%
62.2%
Q1 24
73.7%
65.1%
Operating Margin
CCEL
CCEL
FORA
FORA
Q4 25
-50.6%
-24.4%
Q3 25
24.3%
-6.1%
Q2 25
18.8%
0.6%
Q1 25
13.3%
-19.8%
Q4 24
-1.5%
-24.9%
Q3 24
17.2%
-17.0%
Q2 24
17.3%
-62.2%
Q1 24
10.5%
-36.3%
Net Margin
CCEL
CCEL
FORA
FORA
Q4 25
-48.7%
-22.9%
Q3 25
9.6%
-1.9%
Q2 25
4.5%
3.0%
Q1 25
3.5%
-16.0%
Q4 24
-23.2%
3.4%
Q3 24
13.0%
-4.4%
Q2 24
8.2%
-53.4%
Q1 24
7.1%
-24.9%
EPS (diluted)
CCEL
CCEL
FORA
FORA
Q4 25
$-0.46
$-0.06
Q3 25
$0.09
$0.00
Q2 25
$0.04
$0.01
Q1 25
$0.03
$-0.04
Q4 24
$-0.23
$0.01
Q3 24
$0.13
$-0.01
Q2 24
$0.08
$-0.08
Q1 24
$0.07
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCEL
CCEL
FORA
FORA
Cash + ST InvestmentsLiquidity on hand
$3.3M
$31.6M
Total DebtLower is stronger
$8.4M
Stockholders' EquityBook value
$-18.6M
$29.8M
Total Assets
$61.7M
$44.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCEL
CCEL
FORA
FORA
Q4 25
$3.3M
$31.6M
Q3 25
$3.2M
$28.2M
Q2 25
$4.4M
$35.6M
Q1 25
$3.5M
$35.7M
Q4 24
$3.5M
$35.1M
Q3 24
$2.1M
$49.4M
Q2 24
$1.5M
$48.0M
Q1 24
$979.6K
$47.4M
Total Debt
CCEL
CCEL
FORA
FORA
Q4 25
$8.4M
Q3 25
$8.4M
Q2 25
$8.4M
Q1 25
$8.5M
Q4 24
$8.5M
Q3 24
$8.5M
Q2 24
$8.5M
Q1 24
$8.6M
Stockholders' Equity
CCEL
CCEL
FORA
FORA
Q4 25
$-18.6M
$29.8M
Q3 25
$-14.8M
$31.1M
Q2 25
$-15.6M
$30.9M
Q1 25
$-14.7M
$30.0M
Q4 24
$-13.2M
$30.1M
Q3 24
$-9.6M
$28.4M
Q2 24
$-10.7M
$27.2M
Q1 24
$-10.3M
$28.1M
Total Assets
CCEL
CCEL
FORA
FORA
Q4 25
$61.7M
$44.1M
Q3 25
$63.2M
$41.3M
Q2 25
$64.4M
$48.5M
Q1 25
$64.4M
$48.6M
Q4 24
$64.7M
$47.2M
Q3 24
$62.9M
$57.5M
Q2 24
$62.6M
$58.4M
Q1 24
$61.7M
$57.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCEL
CCEL
FORA
FORA
Operating Cash FlowLast quarter
$1.3M
$3.2M
Free Cash FlowOCF − Capex
$1.2M
FCF MarginFCF / Revenue
15.5%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCEL
CCEL
FORA
FORA
Q4 25
$1.3M
$3.2M
Q3 25
$2.5M
$-439.7K
Q2 25
$707.0K
$-344.5K
Q1 25
$954.1K
$448.2K
Q4 24
$2.2M
$1.7M
Q3 24
$2.4M
$764.1K
Q2 24
$1.8M
$-23.1K
Q1 24
$-356.9K
$-2.2M
Free Cash Flow
CCEL
CCEL
FORA
FORA
Q4 25
$1.2M
Q3 25
$2.5M
Q2 25
$644.6K
Q1 25
$892.0K
Q4 24
$2.1M
Q3 24
$2.3M
Q2 24
$21.5K
Q1 24
$-814.6K
FCF Margin
CCEL
CCEL
FORA
FORA
Q4 25
15.5%
Q3 25
31.9%
Q2 25
8.1%
Q1 25
11.2%
Q4 24
26.8%
Q3 24
27.9%
Q2 24
0.3%
Q1 24
-10.4%
Capex Intensity
CCEL
CCEL
FORA
FORA
Q4 25
0.9%
Q3 25
0.5%
Q2 25
0.8%
Q1 25
0.8%
Q4 24
0.1%
0.0%
Q3 24
2.3%
0.0%
Q2 24
21.8%
0.0%
Q1 24
5.8%
0.0%
Cash Conversion
CCEL
CCEL
FORA
FORA
Q4 25
Q3 25
3.38×
Q2 25
1.99×
-1.53×
Q1 25
3.37×
Q4 24
8.76×
Q3 24
2.32×
Q2 24
2.70×
Q1 24
-0.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCEL
CCEL

Segment breakdown not available.

FORA
FORA

Financial Services Revenues$7.3M92%
Other$669.0K8%

Related Comparisons